Patents by Inventor Bengt Krister Bokvist

Bengt Krister Bokvist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP and GLP-1 co-agonist compounds
    Patent number: 9474780
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: October 25, 2016
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • GIP AND GLP-1 CO-AGONIST COMPOUNDS
    Publication number: 20160199438
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Application
    Filed: January 5, 2016
    Publication date: July 14, 2016
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7897573
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20100009916
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 14, 2010
    Inventors: BENGT KRISTER BOKVIST, LIANSHAN ZHANG, JORGE ALSINA-FERNANDEZ
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7582608
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20090118167
    Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.
    Type: Application
    Filed: August 11, 2005
    Publication date: May 7, 2009
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080318845
    Abstract: The present invention relates to peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: December 25, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080234198
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: October 24, 2006
    Publication date: September 25, 2008
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Apac2 Receptor Peptide Agonists
    Publication number: 20080194482
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 28, 2006
    Publication date: August 14, 2008
    Inventors: Jorge Alsina-Fernandez, Bengt Krister Bokvist, Lianshan Zhang
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080146500
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: June 19, 2008
    Inventors: Bengt Krister Bokvist, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20080096811
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: May 19, 2005
    Publication date: April 24, 2008
    Applicant: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Jesper Lindgren Gromada, Robert Chadwick Cummins, Wolfgang Glaesner, John Philip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez
  • Selective Vpac2 Receptor Peptide Agonists
    Publication number: 20080085860
    Abstract: The present invention encompasses PEGylated peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: August 11, 2005
    Publication date: April 10, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bengt Krister Bokvist, John Phillip Mayer, Lianshan Zhang, Jorge Alsina-Fernandez, Andrew Mark Vick